Hypertension:快速筛查原发性醛固酮增多症的新型化学发光免疫分析法!

2017-06-27 xing.T MedSci原创

这种新的测量方法被认为是传统的放射免疫分析法临床上可靠的替代选择,它可以为从大量临床高血压患者中鉴别诊断原发性醛固酮增多症患者提供了更好的通量和成本效益。

测定血浆醛固酮和肾素浓度或活性在选择降压药物和检测高血压患者醛固酮增多症中是很有用的。然而,用放射免疫法测定结果需要几天的时间,而且长期以来一直在期待更快速的检测方法。

近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员开发了一种新的化学发光免疫分析方法,它能在10分钟内通过同时使用抗体固定的磁性粒子快速聚集和分散的全自动检测法来测定醛固酮和肾素的浓度。研究人员对这种新开发的实验为基础的筛查方法的诊断能力进行了临床验证,研究人员将125例原发性醛固酮增多症患者和97例原发性高血压患者进行了区分。

研究人员发现这项新检测方法的结果与放射免疫测定(醛固酮、有活性的肾素浓度和肾素活性)和液相色谱-串联质谱(醛固酮)的结果显著相关。这一新方法的分析灵敏度尤其是有活性的肾素实验为0.1pg/ml,其结果优于放射免疫法(2pg/ml)。研究人员将醛固酮肾素浓度比值为6(ng/dl vs. pg/ml)作为区分原发性醛固酮增多症与原发性高血压的临界值,其敏感性为92%,特异性为76.3%。

这种新的测量方法被认为是传统的放射免疫分析法临床上可靠的替代选择,它可以为从大量临床高血压患者中鉴别诊断原发性醛固酮增多症患者提供了更好的通量和成本效益。

原始出处:

Ryo Morimoto,et al. Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.Hypertension.2017. https://doi.org/10.1161/HYPERTENSIONAHA.117.09078

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2018-02-21 feather89
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-06-29 cmsvly
  7. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1846557, encodeId=d981184655e98, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Sep 19 11:57:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928157, encodeId=afc9192815ea8, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Apr 20 20:57:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080063, encodeId=a07520800637e, content=<a href='/topic/show?id=5efa956449d' target=_blank style='color:#2F92EE;'>#醛固酮增多症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95644, encryptionId=5efa956449d, topicName=醛固酮增多症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu May 24 05:57:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038696, encodeId=65032038696d2, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Dec 26 19:57:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726518, encodeId=ddea1e2651879, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Feb 21 03:57:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379222, encodeId=3e0913e9222f7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501174, encodeId=7b4315011e4b3, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Jun 29 01:57:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215947, encodeId=239421594ea1, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Jun 27 12:09:39 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-06-27 dhzzm

    学习了分享了

    0

相关资讯

J Hypertens:原发性醛固酮增多症患者血浆中半乳糖凝集素-3的意义!

原发性醛固酮增多症患者血浆Gal-3浓度相比于原发性高血压患者并不升高,并且其水平在肾上腺切除后并不降低。这些结果与以前的研究不一致,并不支持在原发性醛固酮增多症患者血浆中Gal-3在心血管疾病风险增加中的病理生理作用。

JCEM:肾素表型的特征——血管疾病、自发醛固酮增多症以及盐皮质激素受体激活

在目前的诊断标准中,原发性醛固酮增多症(PA)有轻度自发醛固酮分泌物的情况可能还未被发现。研究是否缺乏刺激肾素的能力,作为未被发现的自主醛固酮分泌和盐皮质激素受体(MR)激活的一个生物标记。

JCEM:原发性醛固酮增多症的遗传和组织病理学间的异质性

这一病例凸显了在单个原发性醛固酮增多症(PA)患者在组织学、类固醇生成和体细胞突变方面出现的多发性肾上腺皮质腺瘤的复杂的肿瘤异质性。这些发现表明,原发性醛固酮增多症(PA)的并发症状可能涉及多样化的、多功能性的肾上腺腺瘤。

Lancet Diabetes Endo:单侧肾上腺切除的原发性醛固酮增多症效果评价

大多数患者从肾上腺切除术中获益,年轻患者和女性患者更容易获得良好的手术结果

SCI REP:比较原发性醛固酮增多症患者和原发性高血压患者微血管和大血管的变化!

总之,原发性醛固酮增多症患者相比于原发性高血压患者AVR发生了显著的改变,它可以代表微血管重塑的一个早期和更可靠的指标。

J Hypertens:原发性醛固酮增多症患者新发糖尿病的风险如何?

由此可见,原发性醛固酮增多症患者行肾上腺切除术降低了NODM的发生和全因死亡率的风险,与匹配的高血压对照者相比。这一观察结果增加了更多的证据来表明原发性醛固酮增多症与较高的代谢综合征和长期死亡率风险相关。